In the setting of KRAS/STK11 co-mutation, this may change in the future with the recent FDA approval of the KRAS(G12C) inhibitor sotorasib32 and pre-clinical data suggesting that KRAS(G12C) inhibitors drive anti-tumor immunity33. Here, KRAS is linked to neoplasm.